AroCell expands its distribution network and signs distribution agreement with Inveniolife

AroCell AB (publ) announce today that a distribution agreement has been signed with the Mumbai based company Inveniolife Technology Pvt. Ltd. for the promotion and distribution of the AroCell TK 210™ ELISA in India.

AroCell’s TK 210 ELISA measures concentration levels of thymidine kinase 1 (TK 1) in blood samples and provides valuable information about cell proliferation and disruption in patients with cancer tumors. TK 210 ELISA may also support clinicians to optimize treatment and estimate the risk of recurrence.

"We are looking forward to this new collaboration with Inveniolife for the distribution and promotion of AroCell TK 210 ELISA in India”, says Michael Brobjer, AroCell’s CEO. "This is in line with our strategy to reach all major markets with our product by collaboration with top line distributors. Inventiolife is a well established distributor for the drug discovery, pharma and clinical market in India and has a strong sales team covering academic institutions, CROs and drug discovery companies throughout India.”

This agreement supports AroCell´s commercialization strategy to make AroCell TK 210 ELISA widely available and to facilitate the use of the product in clinical research, routine clinical laboratories as well as for drug development within the pharmaceutical industry.

For more information:
Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

AroCell is obliged to make public this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Michael Brobjer, May 2, 2019 at 08:00.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90.
For more information; www.arocell.com

Attachment

• PM ENG 2019-05-02 Final